Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer
Standard
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer : a Critical Review on the Background and Clinical Utility. / Sinn, P; Aulmann, S; Wirtz, R; Schott, S; Marmé, F; Varga, Z; Lebeau, A; Kreipe, H; Schneeweiss, A.
in: GEBURTSH FRAUENHEILK, Jahrgang 73, Nr. 9, 01.09.2013, S. 932-940.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer
T2 - a Critical Review on the Background and Clinical Utility
AU - Sinn, P
AU - Aulmann, S
AU - Wirtz, R
AU - Schott, S
AU - Marmé, F
AU - Varga, Z
AU - Lebeau, A
AU - Kreipe, H
AU - Schneeweiss, A
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.
AB - Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.
U2 - 10.1055/s-0033-1350831
DO - 10.1055/s-0033-1350831
M3 - SCORING: Journal article
C2 - 24771945
VL - 73
SP - 932
EP - 940
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 9
ER -